Use of rapamycin as a therapeutic agent in the development of cancer has been studied since this drug specifically inhibits mTOR kinase by causing 4EBP hypophosphorylation, resulting in eIF4E hijacking [1,2,37]. This evidence concerns the gene EIF4E and cancer.